Richard Bleicher named chief of new Division of Breast Surgery at Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Richard Bleicher

Richard Bleicher, a professor in the Department of Surgical Oncology and clinical director of the Breast Service Line, has been promoted to chief of the new Division of Breast Surgery at Fox Chase Cancer Center. 

The newly formed Division of Breast Surgery was created to focus efforts at Fox Chase on increasing access for breast cancer patients, as well as on clinical trials and research. In his new role, Bleicher will oversee the division’s programs, research portfolio, and all clinical activities. Additionally, he will provide support for the recruitment of new faculty and the growth of the breast program at all Fox Chase satellite campuses, as well as lead and manage the division. 

Bleicher has been instrumental in expanding the breast faculty within the department and growing the breast surgical program in volume, location, and scope. He will continue to serve as the clinical director of the Breast Service Line at Fox Chase, a position he has held since June 2023. 

Bleicher specializes in breast cancer with a focus on novel treatment modalities, clinical trials, and cosmetic outcomes, but he is most highly recognized and cited for his research regarding the impact of timeliness and delays on breast cancer treatment. His work is the basis for two current Commission on Cancer national quality measures. 

He frequently deals with cases that are not commonly seen by other clinicians, including unusual pathology results, complex cases, and rare clinical situations such as male breast cancer. His research interests include health services research, breast imaging, population studies, sentinel node biopsy in breast cancer, and disparities in breast cancer, among others. 

Table of Contents

YOU MAY BE INTERESTED IN

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA. 
Novartis announced results from an updated analysis of the pivotal phase III NATALEE trial of Kisqali (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy. Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P<0.0001), compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login